Brazil Healthcare Virus Testing

Brazil’s Ministry of Health last month officially rolled-out the use of dengue NS1 antigen test kits by the Unified Health System (SUS), formalizing distribution that had taken place adhoc since 2024. Dengue remains a major public health issue in Brazil, and the NS1 antigen tests reinforce early diagnostic capacity by enabling the detection of acute dengue infection within the first five days of symptoms. As result, Brazil is hoping to improve disease surveillance, clinical management, and reduce the occurrence of severe cases and fatalities.  

Brazil continues expanding its public health infrastructure for early diagnosis of arboviruses such as dengue, Zika, chikungunya, and yellow fever through rapid tests, molecular diagnostics, laboratory networks, and digital surveillance systems integrated into SUS. This expansion could see demand for arbovirus diagnostic kits reach $120 million annually by 2028.

The growth in demand for test kits is creating opportunities for U.S. healthcare technology and diagnostics companies able to offer rapid tests, molecular and point-of-care platforms, laboratory automation, AI-enabled surveillance tools, interoperability solutions, and cold-chain technologies. Further, Brazil’s focus on outbreak preparedness, decentralized testing, and epidemiological intelligence aligns with U.S. strengths in infectious disease diagnostics and public health technologies, creating partnership opportunities with public laboratories, hospitals, distributors, research institutes, and government agencies.

For more information, please contact Jefferson Oliveira, Senior Commercial Specialist with the U.S. Commercial Service at the U.S. Consulate in São Paulo at Jefferson.Oliveira@trade.gov.  

For more market intelligence please visit: Market Intelligence Articles